– New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases – The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery – Approval of the new delivery system follows first implants of the company’s next-generation […]
Coronary/Structural Heart
V-Wave Receives CE Mark for the Ventura™ Interatrial Shunt System
CAESAREA, Israel and AGOURA HILLS, Calif., March 5, 2020 /PRNewswire/ — V-Wave Ltd., a privately held medical device company developing novel implantable devices for the treatment of Heart Failure (HF), today announced that its Ventura™ Interatrial Shunt System received CE Mark and is now approved to be marketed for use in the European Union. “More than 26 […]
“Grindeks” has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB
JSC “Grindeks” announces that it has completed the Phase 1 clinical study of its new investigational medicinal product metyl-GBB. This new investigational medicinal product is intended for the treatment of cardiovascular diseases. This treatment will have a unique therapeutic advantage – the new medicine will be available in both parenteral […]
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
Los Angeles, CA, March 02, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announced it has filed an 8K with the Securities and Exchange Commission (SEC) regarding a presentation on SofPulse® their companies flagship Electroceutical® device. The 8K will be utilized to expand the current US […]
Itamar™ Medical and Clalit Research Institute Establish Research Collaboration to Explore WatchPAT Signals’ Ability to Predict Health Outcomes Using Existing Big Data and Artificial Intelligence
Study will evaluate how raw signals from tens of thousands of WatchPAT recordings conducted over the last 10 years in combination with health medical records can be leveraged to predict cardiovascular outcomes CAESAREA, Israel, March 02, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology […]
BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial
REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failure SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz […]
CryoLife Receives CE Mark for On-X® Ascending Aortic Prosthesis
ATLANTA, Feb. 27, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union. The On-X AAP is indicated for the treatment of diseased, damaged or malfunctioning […]
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LONDON–(BUSINESS WIRE)–Feb. 25, 2020– LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler® devices. The modification includes the installation of a 3T Aerosol Collection Set, as well as testing that demonstrates the effectiveness of […]
CHF Solutions receives 510(k) clearance for Aquadex SmartFlow™ system in Pediatric Patients Weighing 20kg or More
EDEN PRAIRIE, Minn., Feb. 26, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced FDA 510(k) clearance in the U.S. of its next generation Aquadex SmartFlow console for use in adult and pediatric patients who weigh 20kg or more. The console is a simple, gentle, and smart solution for treatment of patients suffering from hypervolemia […]
Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy
ZURICH, Feb. 27, 2020 /PRNewswire/ — Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded and aggregated […]



